Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Lymphoblastic Leukemia
39%
Acute Myeloid Leukemia
36%
Overall Survival
33%
Graft-versus-host Disease (GvHD)
24%
Confidence Interval
21%
Hazard Ratio
19%
Minimal Residual Disease
19%
Non-relapse Mortality
19%
Multiple Myeloma
18%
Fludarabine
18%
Busulfan
17%
Complete Remission
17%
Progression-free Survival
16%
Chimeric Antigen Receptor T-cell Therapy
15%
Myelodysplastic Syndrome
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Transplantation
14%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
14%
Hematopoietic Stem Cell Transplantation
14%
Hematopoietic Cell Transplantation
13%
Unrelated Donor
13%
Relapsed or Refractory
12%
High Risk
11%
Transplant Outcomes
11%
Pretransplant
11%
Post-transplantation Cyclophosphamide (PTCy)
11%
Melphalan
11%
First Complete Remission
10%
Gemtuzumab Ozogamicin
10%
Leukemia Patients
9%
Chemotherapy
9%
Conditioning Regimen
9%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
9%
Stem Cell Transplantation
9%
Reduced-intensity Conditioning
9%
Myeloablative
9%
Multiple Myeloma Patients
8%
Tyrosine Kinase Inhibitor
8%
Adult Patients
8%
Multivariate Analysis
8%
Older Patients
7%
Allogeneic Transplantation
7%
CD19
7%
Complete Response
7%
Older Adults
7%
Haploidentical
7%
Hyper-CVAD
6%
Relapse Risk
6%
Large B-cell Lymphoma
6%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
49%
Hematopoietic Cell
42%
Transplantation
42%
Overall Survival
40%
Acute Myeloid Leukemia
38%
Cell Transplantation
35%
Multiple Myeloma
24%
Diseases
23%
Allogeneic Stem Cell Transplantation
21%
Minimal Residual Disease
21%
Progression Free Survival
20%
Hazard Ratio
20%
Hematopoietic Stem Cell Transplantation
19%
Myelodysplastic Syndrome
18%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
15%
Stem Cell Transplant
15%
Autologous Hematopoietic Stem Cell Transplantation
14%
T Cell
13%
Busulfan
13%
Autologous Stem Cell Transplantation
12%
Fludarabine
11%
Allograft
10%
Philadelphia 1 Chromosome
10%
Graft Versus Host Reaction
10%
Tyrosine-Kinase Inhibitor
10%
Chimeric Antigen Receptor
10%
Conditioning
9%
Melphalan
9%
Multivariate Analysis
8%
Malignant Neoplasm
8%
Stem Cell Therapy
8%
Cell Therapy
8%
Large-Cell Lymphoma
8%
Leukemia
8%
Chimeric Antigen Receptor T-Cell
7%
Inotuzumab Ozogamicin
7%
Acute B-Cell Lymphoblastic Leukemia
7%
Reduced Intensity Conditioning
7%
Clinical Trial
7%
Cyclophosphamide
6%
Comorbidity
6%
Adolescence
6%
B Cell
6%
Acute Lymphocytic Leukemia
6%
Cumulative Incidence
6%
Lenalidomide
6%
Chronic Myelogenous Leukemia
5%
Acute Graft Versus Host Disease
5%
Cytokine Release Syndrome
5%
Immunology and Microbiology
Hematopoietic Cell
41%
Cell Transplantation
37%
Overall Survival
35%
Myeloid
30%
Conditioning
26%
Multiple Myeloma
24%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Progression Free Survival
19%
Hematopoietic Stem Cell Transplantation
18%
Graft-Versus-Host Disease
17%
T Cell
17%
Allogeneic Stem Cell Transplantation
17%
Cyclophosphamide
16%
Allograft
11%
B Cell
11%
Acute Graft Versus Host Disease
11%
Autologous Hematopoietic Stem Cell Transplantation
10%
Chimeric Antigen Receptor
9%
Autologous Stem Cell Transplantation
9%
CD19
8%
Drug Megadose
8%
Engraftment
8%
Stem Cell Transplant
7%
Chimeric Antigen Receptor T-Cell Therapy
7%
Philadelphia 1 Chromosome
7%
Tyrosine
6%
Lenalidomide
5%
Stem Cell
5%
Cord Blood Stem Cell Transplantation
5%
Inotuzumab Ozogamicin
5%
Chronic Graft Versus Host Disease
5%
Disease Free Survival
5%